Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Geron Corp
(NQ:
GERN
)
1.860
-0.130 (-6.53%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Geron Corp
< Previous
1
2
3
4
Next >
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
Today 5:00 EST
From
Geron Corporation
Via
Business Wire
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
November 28, 2023
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2023
From
Geron Corporation
Via
Business Wire
Geron to Participate at Upcoming Investor Conferences in November
November 07, 2023
From
Geron Corporation
Via
Business Wire
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
November 02, 2023
From
Geron Corporation
Via
Business Wire
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
November 02, 2023
From
Geron Corporation
Via
Business Wire
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
October 26, 2023
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 19, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
September 29, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
September 11, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
September 07, 2023
From
Geron Corporation
Via
Business Wire
Geron to Participate in the Baird 2023 Global Healthcare Conference
September 05, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
August 22, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
August 21, 2023
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
Geron Corporation
Via
Business Wire
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
August 03, 2023
From
Geron Corporation
Via
Business Wire
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
June 29, 2023
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
June 20, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
June 13, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
June 12, 2023
From
Geron Corporation
Via
Business Wire
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Geron Corporation
Via
Business Wire
Geron to Host Virtual Investor Event on June 14, 2023
June 06, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
June 02, 2023
From
Geron Corporation
Via
Business Wire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
May 31, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
May 25, 2023
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2023
From
Geron Corporation
Via
Business Wire
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
May 11, 2023
From
Geron Corporation
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.